Our member Hemispherian closed its first funding round and appointed Masha Strømme as Chair of the Board last week.
The Norwegian pre-clinical pharmaceutical company Hemispherian closed a successful seed financing round last week.
The recently acquired funds will go to financing the company’s activities over the next year, develop its pre-clinical pipeline and take its lead product into clinical development.
The seed financing round was led by PAACS Invest and Investinor who partnered with American and British investors.
Dr Masha Strømme from PAACS Invest has also been appointed to chair the Board of Directors.
“Hemispherian’s compelling pre-clinical data sets the stage for the first epigenetic therapeutic to target the activation of the TET2 enzyme resulting in increased 5-hydroxymethylcytosine (5-hmC) and selective cancer cell death. We look forward to contributing to building Hemispherian and moving its promising pipeline towards the clinic,” commented Dr Masha Strømme, Chair of the Board, Hemispherian.
Hemispherian is a start-up company working on the development of a new class of cancer therapeutics, which are targeted towards some of the most aggressive kinds of cancer. One of the cancer types the company is investigating a treatment for is glioblastoma multiforme, a form of brain cancer.
Hemispherian has been a member of Oslo Cancer Cluster since 2020.
For more information, please visit https://www.hemispherian.com